Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group.

MLA

Eichenauer, D. A., et al. “Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Results of a Phase II Study from the German Hodgkin Study Group.” Leukemia, vol. 30, no. 6, June 2016, pp. 1425–27. EBSCOhost, https://doi.org/10.1038/leu.2015.321.

APA

Eichenauer, D. A., Goergen, H., Plütschow, A., Wongso, D., Behringer, K., Kreissl, S., Thielen, I., Halbsguth, T., Bröckelmann, P. J., Fuchs, M., Böll, B., von Tresckow, B., Borchmann, P., & Engert, A. (2016). Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group. Leukemia, 30(6), 1425–1427. https://doi.org/10.1038/leu.2015.321

Chicago

Eichenauer, D A, H Goergen, A Plütschow, D Wongso, K Behringer, S Kreissl, I Thielen, et al. 2016. “Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Results of a Phase II Study from the German Hodgkin Study Group.” Leukemia 30 (6): 1425–27. doi:10.1038/leu.2015.321.